Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster presentation 1

1122 - Predictive factor of metastatic castration-resistant prostate cancer patients' poor response to secondary alternative antiandrogen therapy with flutamide


19 Dec 2015


Poster presentation 1


Masato Yasui


Annals of Oncology (2015) 26 (suppl_9): 71-79. 10.1093/annonc/mdv524


M. Yasui1, S. Yoneyama1, K. Uemura1, T. Kawahara1, Y. Hattori1, J. Teranishi1, J. Ohta2, Y. Yokomizo3, Y. Masahiro3, T. Masataka4, H. Uemura1, Y. Miyoshi1

Author affiliations

  • 1 Department Of Urology And Renal Transplantation, Yokohama City University Medical Center, 232-0024 - Yokohama/JP
  • 2 Department Of Urology, Yokohama Municipal Citizen's Hospital, Yokohama/JP
  • 3 Department Of Urology, Yokohama City University Hospital, Yokohama/JP
  • 4 Department Of Biostatistics And Epidemiology, Yokohama City University Hospital, Yokohama/JP


Abstract 1122


Recently, new androgen pathway inhibitors, abiraterone and enzalutamide, are demonstrated to improve overall survival for metastatic castration-resistant prostate cancer (mCRPC). In Japan, alternative antiandrogen (AA) as second-line hormonal therapy for mCRPC that relapses after initial hormone therapy have been commonly used before new androgen pathway inhibitors. In this study, we attempted to identify the predictive factors for efficacy of AA as second-line hormone therapy.


We identified consecutive 43 metastatic prostate cancer patients treated with AA as second-line hormonal therapy (bicalutamide to flutamide). All patients were treated with maximum androgen blockade (MAB) initially and evaluated antiandrogen withdrawal syndrome after relapse. We analyzed the correlation between progression-free survival (PFS) of AA and clinicopathological characteristics, including patients' age, initial PSA levels, PSA levels at flutamide induction, Gleason scores, T stage, N stage, extent of disease (EOD) classifications on bone scan, and the previous duration of prostate cancer sensitivity to MAB.


The median duration of prostate cancer sensitivity to MAB was 2.8 months (range: 0.0-73.1+ months). In univariate analysis, patients' age and the previous duration of prostate cancer sensitivity to MAB were correlated with poor PFS. In multivariate analysis, two significant risk factors for poor PFS were identified; EOD classifications (3-4 vs 1-2; HR 2.41, 95% CI 1.01-5.76, p = 0.046) and N stage (1 vs 0; HR 2.76, 95% CI 1.00-7.60, p = 0.049). We stratified the patients into two cohorts with low risk (0-1 risk factor present) and high risk (2 risk factors present). We found a significant difference in PFS among risk groups (median PFS 3.6 months vs 0.9, p < 0.000).


EOD classifications on bone scan and N stage were the significant predictive factor for efficacy of AA as second-line hormone therapy in patients with mCRPC. These findings might support that decision-making of when to start the new AR pathway inhibitors.

Clinical trial identification


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings